InvestorsHub on MSN
Jazz Pharmaceuticals wins FDA approval for Ziihera regimens in first-line HER2+ advanced GEA
Jazz Pharmaceuticals (NASDAQ:JAZZ) has secured FDA approval for two Ziihera-containing regimens in first-line HER2-positive advanced gastroesophageal adenocarcinoma, expanding the drug into an earlier ...
Clinical Trials Arena on MSN
Jazz reports Phase III trial interim results for Ziihera combination
The combination showed a statistically significant overall survival benefit compared with trastuzumab plus chemotherapy.
Jazz Pharmaceuticals Plc (NASDAQ: JAZZ) shares are popping on Monday following the company’s positive results of its Phase 3 HERIZON-GEA-01 trial, which assessed Ziihera in combination with ...
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced second interim top-line overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial showing that Ziihera ® (zanidatamab-hrii) in ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Jazz Pharmaceuticals has been granted US approval for two combinations of its cancer drug Ziihera for people with advanced HER2-positive gastroesophageal adenocarcinoma. The FDA’s decision clears ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results